Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia.

Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia.

Item
http://www.wikidata.org/entity/Q42473053
Therapeutic targeting of redox signaling in myofibroblast differentiation and age-related fibrotic diseaseTissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts.Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling.The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunctionPhosphodiesterase-5 expression and function in the lower urinary tract: a critical review.Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis.Redox signaling as a therapeutic target to inhibit myofibroblast activation in degenerative fibrotic diseaseDo baseline estrogen and testosterone affect lower urinary tract symptoms (LUTS) prior to or after pharmacologic treatment with tadalafil?Dickkopf-related protein 3 promotes pathogenic stromal remodeling in benign prostatic hyperplasia and prostate cancer.Expression of a recombinant full-length LRP1B receptor in human non-small cell lung cancer cells confirms the postulated growth-suppressing function of this large LDL receptor family member.Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit.Phosphodiesterase type 5 and cancers: progress and challenges.Phosphodiesterase Type 5 Inhibitor Use Following Radical Prostatectomy is not Associated with an Increased Risk of Biochemical Recurrence.Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling.
P2860

Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia.

Item
http://www.wikidata.org/entity/Q42473053
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Attenuated proliferation and t ...... benign prostatic hyperplasia.
@en
Attenuated proliferation and t ...... benign prostatic hyperplasia.
@nl
type
label
Attenuated proliferation and t ...... benign prostatic hyperplasia.
@en
Attenuated proliferation and t ...... benign prostatic hyperplasia.
@nl
prefLabel
Attenuated proliferation and t ...... benign prostatic hyperplasia.
@en
Attenuated proliferation and t ...... benign prostatic hyperplasia.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Attenuated proliferation and t ...... f benign prostatic hyperplasia
@en
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698